Eris Lifesciences Limited CC-Sep23.pdf · 2023-11-08
If you see for the second quarter while our standalone branded pharma business has grown at a 13% kind of a rate, the consol growth for us is only around 10%. It is likely that the trade generics business is having an impact as far as our consol growth is concerned . When do you see this impact waning off and the standalone growth to start mirroring on the consol growth as well?
This organic growth of 7% to 8% which you indicated is for this 97% of the business?